Here below are the publications (1) participated by Sara De Dosso along with Genti Xhepa (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch
Sara De Dossois currently collaborating with
Istituto Oncologico Svizzera Italiana (IOSI) (Rif. IOSI)
Via Gallino 12 (ex Via Ospedale)
6500 Bellinzona
Sara De Dosso
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Preoperative treatment with metronidazole to evaluate the efficacy in reducing Fusobacterium nucleatum tumor colonization in patients with colorectal cancer (CRC): a proof-of-concept trial (Rif. 18000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Preoperative treatment with metronidazole to evaluate the efficacy in reducing Fusobacterium nucleatum tumor colonization in patients with colorectal cancer (CRC): a proof-of-concept trial (Rif. 18000 202407)
Sara De Dosso
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (Rif. 17000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (Rif. 17000 202407)
Sara De Dosso
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients (Rif. 08000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients (Rif. 08000 202407)
Sara De Dosso
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
MK-9999-02A Sub-Study: A Phase 1/2 Substudy of the MK 9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination with Other Anticancer Agents in Gastrointestinal Cancers. (Rif. 38000 202408)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
MK-9999-02A Sub-Study: A Phase 1/2 Substudy of the MK 9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination with Other Anticancer Agents in Gastrointestinal Cancers. (Rif. 38000 202408)